Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2024 | Ibuprofen | Review

Medication use during pregnancy and the risk of gastroschisis: a systematic review and meta-analysis of observational studies

Authors: Silvia Baldacci, Michele Santoro, Lorena Mezzasalma, Anna Pierini, Alessio Coi

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Abstract

Objectives

The aetiology of gastroschisis is considered multifactorial. We conducted a systematic review and meta-analysis to assess whether the use of medications during pregnancy, is associated with the risk of gastroschisis in offspring.

Methods

PubMed, EMBASE, and Scopus were searched from 1st January 1990 to 31st December 2020 to identify observational studies examining the association between medication use during pregnancy and the risk of gastroschisis. The Newcastle–Ottawa Scale was used for the quality assessment of the individual studies. We pooled adjusted measures using a random-effect model to estimate relative risk [RR] and the 95% confidence interval [CI]. I² statistic for heterogeneity and publication bias was calculated.

Results

Eighteen studies providing data on 751,954 pregnancies were included in the meta-analysis. Pooled RRs showed significant associations between aspirin (RR 1.66, 95% CI 1.16–2.38; I² = 58.3%), oral contraceptives (RR 1.52, 95% CI 1.21–1.92; I² = 22.0%), pseudoephedrine and phenylpropanolamine (RR 1.51, 95% CI 1.16–1.97; I² = 33.2%), ibuprofen (RR 1.42, 95% CI 1.26–1.60; I² = 0.0%), and gastroschisis. No association was observed between paracetamol and gastroschisis (RR 1.16, 95% CI 0.96–1.41; I² = 39.4%).

Conclusions

These results suggest that the exposure in the first trimester of pregnancy to over the counter medications (OTC) such as aspirin, ibuprofen, pseudoephedrine and phenylpropanolamine as well as to oral contraceptives, was associated with an increased risk of gastroschisis. However, these associations are significant only in particular subgroups defined by geographic location, adjustment variables and type of control. Therefore, further research is needed to investigate them as potential risk factors for gastroschisis, to assess their safety in pregnancy and to develop treatment strategies to reduce the risk of gastroschisis in offspring.

PROSPERO registration number: CRD42021287529.

Available only for authorised users

Rittler M, Vauthay L, Mazzitelli N. Gastroschisis is a defect of the umbilical ring: evidence from morphological evaluation of stillborn fetuses. Birth Defects Res A Clin Mol Teratol. 2013;97:198–209.CrossRefPubMed

Bargy F, Beaudoin S. Comprehensive developmental mechanisms in gastroschisis. Fetal Diagn Ther. 2014;36:223–30.CrossRefPubMed

Mastroiacovo P, Lisi A, Castilla EE, Martínez-Frías ML, Bermejo E, Marengo L, et al. Gastroschisis and associated defects: an international study. Am J Med Genet A. 2007;143A(7):660–71. https://doi.org/10.1002/ajmg.a.31607.CrossRefPubMed

Youssef F, Cheong LH, Emil S, Canadian Pediatric Surgery Network (CAPSNet). Gastroschisis outcomes in North America: a comparison of Canada and the United States. J Pediatr Surg. 2016;51(6):891–5. https://doi.org/10.1016/j.jpedsurg.2016.02.046.CrossRefPubMed

Vo LU, Langlois PH. Time trends in prevalence of gastroschisis in Texas, 1999 to 2011: subgroup analyses by maternal and infant characteristics. Birth Defects Res A Clin Mol Teratol. 2015;103(11):928–40. https://doi.org/10.1002/bdra.23438.CrossRefPubMed

Lepigeon K, Van Mieghem T, Vasseur Maurer S, Giannoni E, Baud D. Gastroschisis-what should be told to parents? Prenat Diagn. 2014;34(4):316–26. https://doi.org/10.1002/pd.4305.CrossRefPubMed

Beaudoin S. Insights into the etiology and embryology of gastroschisis. Semin Pediatr Surg. 2018;27(5):283–8. https://doi.org/10.1053/j.sempedsurg.2018.08.005.CrossRefPubMed

Jones AM, Isenburg J, Salemi JL, Arnold KE, Mai CT, Aggarwal D, Arias W, Carrino GE, Ferrell E, Folorunso O, Ibe B, Kirby RS, Krapfl HR, Marengo LK, Mosley BS, Nance AE, Romitti PA, Spadafino J, Stock J, Honein MA. Increasing prevalence of gastroschisis–14 states, 1995–2012. MMWR Morb Mortal Wkly Rep. 2016;65(2):23–6.CrossRefPubMed

Loane M, Dolk H, Bradbury I, EUROCAT Working Group. Increasing prevalence of gastroschisis in Europe 1980–2002: a phenomenon restricted to younger mothers? Paediatr Perinat Epidemiol. 2007;21(4):363–9. https://doi.org/10.1111/j.1365-3016.2007.00820.x.CrossRefPubMed

10.

Castilla EE, Mastroiacovo P, Orioli IM. Gastroschisis: international epidemiology and public health perspectives. Am J Med Genet C Semin Med Genet. 2008;148C(3):162–79. https://doi.org/10.1002/ajmg.c.30181.CrossRefPubMed

11.

Rittler M, Campaña H, Ermini ML, Gili JA, Poletta FA, Pawluk MS, et al. Gastroschisis and young mothers: What makes them different from other mothers of the same age? Birth Defects Res A Clin Mol Teratol. 2015;103(6):536–43. https://doi.org/10.1002/bdra.23374.CrossRefPubMed

12.

Skarsgard ED, Meaney C, Bassil K, Brindle M, Arbour L, Moineddin R, Canadian Pediatric Surgery Network (CAPSNet). Maternal risk factors for gastroschisis in Canada. Birth Defects Res A Clin Mol Teratol. 2015;103(2):111–8. https://doi.org/10.1002/bdra.23349.CrossRefPubMed

13.

Feldkamp ML, Carey JC, Sadler TW. Development of gastroschisis: review of hypotheses, a novel hypothesis, and implications for research. Am J Med Genet A. 2007;143A:639–52.CrossRefPubMed

14.

Werler MM, Mitchell AA, Moore CA, Honein MA, National Birth Defects Prevention Study. Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? Am J Med Genet A. 2009;149A(7):1399–406. https://doi.org/10.1002/ajmg.a.32897.CrossRefPubMedPubMedCentral

15.

Mac Bird T, Robbins JM, Druschel C, Cleves MA, Yang S, Hobbs CA. Demographic and environmental risk factors for gastroschisis and omphalocele in the National Birth Defects Prevention Study. J Pediatr Surg. 2009;44:1546–51. https://doi.org/10.1016/j.jpedsurg.2008.10.109.CrossRefPubMed

16.

Curry JI, McKinney P, Thornton JG, Stringer MD. The aetiology of gastroschisis. BJOG. 2000;107:1339–46. https://doi.org/10.1111/j.1471-0528.2000.tb11645.x.CrossRefPubMed

17.

Rasmussen SA, Frías JL. Non-genetic risk factors for gastroschisis. Am J Med Genet C Semin Med Genet. 2008;148C:199–212. https://doi.org/10.1002/ajmg.c.30175.CrossRefPubMed

18.

Frolov P, Alali J, Klein MD. Clinical risk factors for gastroschisis and omphalocele in humans: a review of the literature. Pediatr Surg Int. 2010;26:1135–48. https://doi.org/10.1007/s00383-010-2701-7.CrossRefPubMed

19.

Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002;187(6):1623–30. https://doi.org/10.1067/mob.2002.127376.CrossRefPubMed

20.

Baldacci S, Santoro M, Coi A, Mezzasalma L, Bianchi F, Pierini A. Lifestyle and sociodemographic risk factors for gastroschisis: a systematic review and meta-analysis. Arch Dis Child. 2020;105(8):756–64. https://doi.org/10.1136/archdischild-2019-318412.CrossRefPubMed

21.

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https://doi.org/10.1136/bmj.n160.CrossRefPubMedPubMedCentral

22.

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Ottawa Scale [Internet]. 2020 Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

23.

Xie P, Xia W, Lowe S, Zhou Z, Ding P, Cheng C, Bentley R, Li Y, Wang Y, Zhou Q, Wu B, Gao J, Feng L, Ma S, Liu H, Sun C. High spicy food intake may increase the risk of esophageal cancer: a meta-analysis and systematic review. Nutr Res. 2022;107:139–51. https://doi.org/10.1016/j.nutres.2022.09.006.CrossRefPubMed

24.

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf. 2019;42(4):529–38. https://doi.org/10.1007/s40264-018-0751-2.CrossRefPubMed

25.

Ma Z, Cao X, Chang Y, Li W, Chen X, Tang NJ. Association between gestational exposure and risk of congenital heart disease: a systematic review and meta-analysis. Environ Res. 2021;197: 111014. https://doi.org/10.1016/j.envres.2021.111014.CrossRefPubMed

26.

Fell M, Dack K, Chummun S, Sandy J, Wren Y, Lewis S. Maternal cigarette smoking and cleft lip and palate: a systematic review and meta-analysis. Cleft Palate Craniofac J. 2022;59(9):1185–200. https://doi.org/10.1177/10556656211040015.CrossRefPubMed

27.

Wang Z, Brauer R, Man KKC, Alfageh B, Mongkhon P, Wong ICK. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4101–23. https://doi.org/10.1111/bcp.14839.CrossRefPubMed

28.

Li P, Qin X, Tao F, Huang K. Maternal exposure to sulfonamides and adverse pregnancy outcomes: a systematic review and meta-analysis. PLoS ONE. 2020;15(12): e0242523. https://doi.org/10.1371/journal.pone.0242523.CrossRefPubMedPubMedCentral

29.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.CrossRefPubMed

30.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral

31.

Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–29. https://doi.org/10.1016/s0895-4356(00)00242-0.CrossRefPubMed

32.

Duval S, Tweedie R. A nonparametric, “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95(449):89–98.

33.

Murad MH, Chu H, Lin L, Wang Z. The effect of publication bias magnitude and direction on the certainty in evidence. BMJ Evid Based Med. 2018;23(3):84–6. https://doi.org/10.1136/bmjebm-2018-110891.CrossRefPubMedPubMedCentral

34.

Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997–2007. Paediatr Perinat Epidemiol. 2013;27(4):340–5. https://doi.org/10.1111/ppe.12064.CrossRefPubMedPubMedCentral

35.

Ailes EC, Gilboa SM, Gill SK, Broussard CS, Crider KS, Berry RJ, et al. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. Birth Defects Res A Clin Mol Teratol. 2016;106(11):940–9. https://doi.org/10.1002/bdra.23570.CrossRefPubMedPubMedCentral

36.

Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684–92. https://doi.org/10.1056/NEJMoa066584.CrossRefPubMed

37.

Anderson KN, Dutton AC, Broussard CS, Farr SL, Lind JN, Visser SN, et al. ADHD medication use during pregnancy and risk for selected birth defects: national birth defects prevention study, 1998–2011. J Atten Disord. 2020;24(3):479–89. https://doi.org/10.1177/1087054718759753.CrossRefPubMed

38.

Anderson KN, Ailes EC, Lind JN, Broussard CS, Bitsko RH, Friedman JM, et al. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997–2011. Schizophr Res. 2020;215:81–8. https://doi.org/10.1016/j.schres.2019.11.019.CrossRefPubMed

39.

Bitsko RH, Reefhuis J, Louik C, Werler M, Feldkamp ML, Waller DK, et al. Periconceptional use of weight loss products including ephedra and the association with birth defects. Birth Defects Res A Clin Mol Teratol. 2008;82(8):553–62. https://doi.org/10.1002/bdra.20472.CrossRefPubMed

40.

Blotière PO, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019;93(2):e167–80. https://doi.org/10.1212/WNL.0000000000007696.CrossRefPubMedPubMedCentral

41.

Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(4):314.e1-11. https://doi.org/10.1016/j.ajog.2010.12.039.CrossRefPubMed

42.

Carter TC, Druschel CM, Romitti PA, Bell EM, Werler MM, Mitchell AA. Antifungal drugs and the risk of selected birth defects. Am J Obstet Gynecol. 2008;198(2):191.e1-7. https://doi.org/10.1016/j.ajog.2007.08.044.CrossRefPubMed

43.

Charlton BM, Mølgaard-Nielsen D, Svanström H, Wohlfahrt J, Pasternak B, Melbye M. Maternal use of oral contraceptives and risk of birth defects in Denmark: prospective, nationwide cohort study. BMJ. 2016;352: h6712. https://doi.org/10.1136/bmj.h6712.CrossRefPubMedPubMedCentral

44.

Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163:978–85. https://doi.org/10.1001/archpediatrics.2009.188.CrossRefPubMed

45.

David AL, Holloway A, Thomasson L, Syngelaki A, Nicolaides K, Patel RR, et al. A case-control study of maternal periconceptual and pregnancy recreational drug use and fetal malformation using hair analysis. PLoS ONE. 2014;9(10): e111038. https://doi.org/10.1371/journal.pone.0111038.CrossRefPubMedPubMedCentral

46.

Draper ES, Rankin J, Tonks AM, Abrams KR, Field DJ, Clarke M, Kurinczuk JJ. Recreational drug use: a major risk factor for gastroschisis? Am J Epidemiol. 2008;167(4):485–91. https://doi.org/10.1093/aje/kwm335.CrossRefPubMed

47.

Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol. 2010;115:109–15. https://doi.org/10.1097/AOG.0b013e3181c52616.CrossRefPubMed

48.

Fisher SC, Van Zutphen AR, Werler MM, Romitti PA, Cunniff C, Browne ML. Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res. 2018;110(19):1433–42. https://doi.org/10.1002/bdr2.1372.CrossRefPubMedPubMedCentral

49.

Furu K, Kieler H, Haglund B, Engeland B, Selmer A, Stephansson R, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350: h2235. https://doi.org/10.1136/bmj.h2235.CrossRef

50.

Garne E, Hansen AV, Morris J, Zaupper L, Addor MC, Barisic I, et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: a European case-malformed control study. J Allergy Clin Immunol. 2015;136(6):1496-1502.e7. https://doi.org/10.1016/j.jaci.2015.05.043.CrossRefPubMed

51.

van Gelder MM, Van Bennekom CM, Louik C, Werler MM, Roeleveld N, Mitchell AA. Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case–control study. BJOG. 2015;122(7):1002–9. https://doi.org/10.1111/1471-0528.13138.CrossRefPubMed

52.

Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol. 2009;85(2):137–50. https://doi.org/10.1002/bdra.20513.CrossRefPubMedPubMedCentral

53.

Howley MM, Papadopoulos EA, Van Bennekom CM, Van Zutphen AR, Carmichael SL, Munsie JW, et al. Asthma medication use and risk of birth defects: National Birth Defects Prevention Study, 1997–2011. J Allergy Clin Immunol Pract. 2020;8(10):3490-3499.e9. https://doi.org/10.1016/j.jaip.2020.07.033.CrossRefPubMedPubMedCentral

54.

Interrante JD, Ailes EC, Lind JN, Anderka M, Feldkamp ML, Werler MM, et al. Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997–2011. Ann Epidemiol. 2017;27(10):645-653.e2. https://doi.org/10.1016/j.annepidem.2017.09.003.CrossRefPubMedPubMedCentral

55.

Jenkins MM, Reefhuis J, Gallagher ML, Mulle JG, Hoffmann TJ, Koontz DA, et al. Maternal smoking, xenobiotic metabolizing enzyme gene variants, and gastroschisis risk. Am J Med Genet A. 2014;164A(6):1454–63. https://doi.org/10.1002/ajmg.a.36478.CrossRefPubMed

56.

Lam PK, Torfs CP, Brand RJ. A low pregnancy body mass index is a risk factor for an offspring with gastroschisis. Epidemiology. 1999;10(6):717–21.CrossRefPubMed

57.

Li Q, Mitchell AA, Werler MM, Yau WP, Hernández-Díaz S. Assessment of antihistamine use in early pregnancy and birth defects. J Allergy Clin Immunol Pract. 2013;1(6):666-74.e1. https://doi.org/10.1016/j.jaip.2013.07.008.CrossRefPubMedPubMedCentral

58.

Lin S, Munsie JP, Herdt-Losavio ML, Bell E, Druschel C, Romitti PA, et al. Maternal asthma medication use and the risk of gastroschisis. Am J Epidemiol. 2008;168(1):73–9. https://doi.org/10.1093/aje/kwn098.CrossRefPubMed

59.

Louik C, Ahrens K, Kerr S, Pyo J, Chambers C, Jones KL, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. Vaccine. 2013;31(44):5033–40. https://doi.org/10.1016/j.vaccine.2013.08.096.CrossRefPubMed

60.

Paranjothy S, Broughton H, Evans A, Huddart S, Drayton M, Jefferson R, et al. The role of maternal nutrition in the aetiology of gastroschisis: an incident case-control study. Int J Epidemiol. 2012;41(4):1141–52. https://doi.org/10.1093/ije/dys092.CrossRefPubMed

61.

Polen KN, Rasmussen SA, Riehle-Colarusso T, Reefhuis J. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997–2007. Birth Defects Res A Clin Mol Teratol. 2013;97(1):28–35. https://doi.org/10.1002/bdra.23096.CrossRefPubMed

62.

Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ. 2015;351: h3190. https://doi.org/10.1136/bmj.h3190.CrossRefPubMedPubMedCentral

63.

Siega-Riz AM, Herring AH, Olshan AF, Smith J, Moore C. The joint effects of maternal prepregnancy body mass index and age on the risk of gastroschisis. Paediatr Perinat Epidemiol. 2008;23:51–7. https://doi.org/10.1111/j.1365-3016.2008.00990.CrossRef

64.

Tinker SC, Reefhuis J, Bitsko RH, Gilboa SM, Mitchell AA, Tran EL, et al. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997–2011. Birth Defects Res. 2019;111(10):613–20. https://doi.org/10.1002/bdr2.1497.CrossRefPubMedPubMedCentral

65.

Torfs CP, Lam PK, Schaffer DM, Brand RJ. Association between mothers’ nutrient intake and their offspring’s risk of gastroschisis. Teratology. 1998;58:241–50.CrossRefPubMed

66.

Wemakor A, Casson K, Garne E, Bakker M, Addor MC, Arriola L, et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol. 2015;30(11):1187–98. https://doi.org/10.1007/s10654-015-0065-y.CrossRefPubMed

67.

Feldkamp ML, Carmichael SL, Shaw GM, Panichello JD, Moore CA, Botto LD. Maternal nutrition and gastroschisis: findings from the National Birth Defects Prevention Study. Am J Obstet Gynecol. 2011;204(5):404.e1-404.e10. https://doi.org/10.1016/j.ajog.2010.12.053.CrossRefPubMed

68.

Freitas AB, Centofanti SF, Osmundo-Junior GS, Rodrigues AS, Francisco RPV, Brizot ML. Risk factors for gastroschisis: a case–control study in a Brazilian population. Int J Gynecol Obstet. 2020;149:347–53. https://doi.org/10.1002/ijgo.13135.CrossRef

69.

Given JE, Loane M, Garne E, Nelen V, Barisic I, Randrianaivo H, et al. Gastroschisis in Europe: a case-malformed–control study of medication and maternal illness during pregnancy as risk factors. Paediatr Perinat Epidemiol. 2017;31(6):549–59. https://doi.org/10.1111/ppe.12401.CrossRefPubMed

70.

Goodman JR, Peck JD, Landmann A, Williams M, Elimian A. An evaluation of nutritional and vasoactive stimulants as risk factors for gastroschisis: a pilot study. J Matern Fetal Neonatal Med. 2019;32(14):2346–53. https://doi.org/10.1080/14767058.2018.1433657.CrossRefPubMed

71.

Martínez-Frías ML, Rodríguez-Pinilla E, Prieto L. Prenatal exposure to salicylates and gastroschisis: a case–control study. Teratology. 1997;56:241–3.CrossRefPubMed

72.

Raitio A, Tauriainen A, Leinonen MK, Syvänen J, Kemppainen T, Löyttyniemi E, et al. Maternal risk factors for gastroschisis: a population-based case-control study. Birth Defects Res. 2020;112(13):989–95. https://doi.org/10.1002/bdr2.1703.CrossRefPubMed

73.

Rebordosa C, Kogevinas M, Horváth-Puhó E, Nørgård B, Morales M, Czeizel AE, et al. Acetaminophen use during pregnancy: effects on risk for congenital abnormalities. Am J Obstet Gynecol. 2008;198:178.e1-178.e1787. https://doi.org/10.1016/j.ajog.2007.08.040.CrossRefPubMed

74.

Robledo-Aceves M, Bobadilla-Morales L, Mellín-Sánchez EL, Corona-Rivera A, Pérez-Molina JJ, Cárdenas-Ruiz Velasco JJ, et al. Prevalence and risk factors for gastroschisis in a public hospital from west México. Congenit Anom (Kyoto). 2015;55(2):73–80. https://doi.org/10.1111/cga.12087.CrossRefPubMed

75.

Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology. 1996;54:84–92.CrossRefPubMed

76.

Waller DK, Gallaway MS, Taylor LG, Ramadhani TA, Canfield MA, Scheuerle A, et al. Use of oral contraceptives in pregnancy and major structural birth defects in offspring. Epidemiology. 2010;21(2):232–9. https://doi.org/10.1097/EDE.0b013e3181c9fbb3.CrossRefPubMed

77.

Werler MM, Guéry E, Waller DK, Parker SE. Gastroschisis and cumulative stressor exposures. Epidemiology. 2018;29(5):721–8. https://doi.org/10.1097/EDE.0000000000000860.CrossRefPubMed

78.

Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology. 2003;14:349–54.CrossRefPubMed

79.

Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 2002;155(1):26–31. https://doi.org/10.1093/aje/155.1.26.CrossRefPubMed

80.

Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology. 1992;45:361–7. https://doi.org/10.1002/tera.1420450407.CrossRefPubMed

81.

Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernández-Díaz S. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 2013;178:198–208. https://doi.org/10.1093/aje/kws427.CrossRefPubMedPubMedCentral

82.

Slone Epidemiology Center at Boston University. The Slone Drug Dictionary. https://www.bu.edu/slone/drug-dictionary/

83.

WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2021. Oslo, 2020. https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/

84.

van Gelder MM, van Rooij IA, Miller RK, Zielhuis GA, de Jong-van den Berg LT, Roeleveld N. Teratogenic mechanisms of medical drugs. Hum Reprod Update. 2010;16(4):378–94. https://doi.org/10.1093/humupd/dmp052.CrossRefPubMed

85.

Toboła-Wróbel K, Pietryga M, Dydowicz P, Napierała M, Brązert J, Florek E. Association of oxidative stress on pregnancy. Oxid Med Cell Longev. 2020;15(2020):6398520. https://doi.org/10.1155/2020/6398520.CrossRef

86.

Feldkamp ML, Enioutina EY, Botto LD, Krikov S, Byrne JL, Geisler WM. Chlamydia trachomatis IgG3 seropositivity is associated with gastroschisis. J Perinatol. 2015;35(11):930–4. https://doi.org/10.1038/jp.2015.115.CrossRefPubMedPubMedCentral

87.

Feldkamp ML, Arnold KE, Krikov S, Reefhuis J, Almli LM, Moore CA. Risk of gastroschisis with maternal genitourinary infections the US National birth defects prevention study 1997–2011. BMJ Open. 2019;9: e026297. https://doi.org/10.1136/bmjopen-2018-026297.CrossRefPubMedPubMedCentral

88.

Yazdy MM, Mitchell AA, Werler MM. Maternal genitourinary infections and the risk of gastroschisis. Am J Epidemiol. 2014;180(5):518–25. https://doi.org/10.1093/aje/kwu157.CrossRefPubMedPubMedCentral

89.

Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM, National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997–2007. Paediatr Perinat Epidemiol. 2013;27(4):340–5. https://doi.org/10.1111/ppe.12064.CrossRefPubMedPubMedCentral

90.

Wang X, Wu Q, Liu A, Anadón A, Rodríguez JL, Martínez-Larrañaga MR, Yuan Z, Martínez MA. Paracetamol: overdose-induced oxidative stress toxicity, metabolism, and protective effects of various compounds in vivo and in vitro. Drug Metab Rev. 2017;49(4):395–437. https://doi.org/10.1080/03602532.2017.1354014.CrossRefPubMed

91.

Lubinsky M. Hypothesis: estrogen-related thrombosis explains the pathogenesis and epidemiology of gastroschisis. Am J Med Genet A. 2012;158A(4):808–11. https://doi.org/10.1002/ajmg.a.35203.CrossRefPubMed

92.

Chen JT, Kotani K. Oral contraceptive therapy increases oxidative stress in pre-menopausal women. Int J Prev Med. 2012;3:893–6.CrossRefPubMedPubMedCentral

93.

Chen JT, Kotani K. Different effects of oral contraceptive and dydrogesterone treatment on oxidative stress levels in premenopausal women. J Clin Med Res. 2018;10:146–53.CrossRefPubMed

94.

De Groote D, Perrier d’Hauterive S, Pintiaux A, Balteau B, Gerday C, Claesen J, Foidart JM. Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18–35 years old. Contraception. 2009;80:187–93.CrossRefPubMed

95.

Finco A, Belcaro G, Cesarone MR. Assessment of the activity of an oral contraceptive on the levels of oxidative stress and changes in oxidative stress after co-treatment with two different types of physiological modulators with antioxidant action. Contraception. 2011;84:418–22.CrossRefPubMed

96.

Pincemail J, Vanbelle S, Gaspard U, Collette G, Haleng J, Cheramy-Bien JP, Charlier C, Chapelle JP, Giet D, Albert A, et al. Effect of different contraceptive methods on the oxidative stress status in women aged 40 48 years from the ELAN study in the province of Liege, Belgium. Hum Reprod. 2007;22:2335–43.CrossRefPubMed

97.

Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol. 2008;111:857–64.CrossRefPubMed

98.

Cauci S, Buligan C, Marangone M, et al. Oxidative stress in female athletes using combined oral contraceptives. Sports Med Open. 2016;2:40. https://doi.org/10.1186/s40798-016-0064-.CrossRefPubMedPubMedCentral

99.

Cauci S, Xodo S, Buligan C, Colaninno C, Barbina M, Barbina G, Francescato MP. Oxidative stress is increased in combined oral contraceptives users and is positively associated with high-sensitivity C-reactive protein. Molecules. 2021;26(4):1070. https://doi.org/10.3390/molecules26041070.CrossRefPubMedPubMedCentral

100.

Holford NH, Buclin T. Safe and effective variability: a criterion for dose individualization. Ther Drug Monit. 2012;34(5):565–8. https://doi.org/10.1097/FTD.0b013e31826aabc3.CrossRefPubMed

Title: Medication use during pregnancy and the risk of gastroschisis: a systematic review and meta-analysis of observational studies
Authors: Silvia Baldacci
Michele Santoro
Lorena Mezzasalma
Anna Pierini
Alessio Coi
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Ibuprofen
Paracetamol
Published in: Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-023-02992-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Medication use during pregnancy and the risk of gastroschisis: a systematic review and meta-analysis of observational studies

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Economic burden of patients with post-surgical chronic and transient hypoparathyroidism in the United States examined using insurance claims data

Implementation of thyroid eye disease registry in Iran: rationale and research protocol

Coexistence of meningioma and craniofacial fibrous dysplasia: a case series of clinicopathological study and literature review

The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers

Inventory of current practices regarding hematopoietic stem cell transplantation in metachromatic leukodystrophy in Europe and neighboring countries

Dysregulation of extracellular matrix and Lysyl Oxidase in Ehlers-Danlos syndrome type IV skin fibroblasts